Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 3
1999 1
2000 2
2002 30
2003 31
2004 57
2005 72
2006 80
2007 98
2008 136
2009 151
2010 181
2011 191
2012 234
2013 255
2014 300
2015 375
2016 376
2017 368
2018 407
2019 457
2020 548
2021 658
2022 727
2023 737
2024 813
2025 951
2026 556

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7,826 results

Results by year

Filters applied: . Clear all
Page 1
The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment.
Chan SL, Sun HC, Xu Y, Zeng H, El-Serag HB, Lee JM, Schwartz ME, Finn RS, Seong J, Wang XW, Paradis V, Abou-Alfa GK, Rimassa L, Kao JH, Zhang BH, Llovet JM, Bruix J, Yip TC, Wong VW, Wong GL, Chan LL, Liu MQ, Gao Q, Shen F, Kelley RK, Cheng AL, Kurosaki M, Toyoda H, Chen WX, Murakami T, Liang P, Zucman-Rossi J, Minami Y, Miyayama S, Wang K, Man K, Hasegawa K, Li Q, Tsuchiya K, Xu L, Chew V, Chow P, Hoshida Y, Lujambio A, Ng IO, Sakamoto M, Park YN, Yau T, Kudo M, Fan J, Zhou J. Chan SL, et al. Among authors: xu l. Lancet. 2025 Aug 16;406(10504):731-778. doi: 10.1016/S0140-6736(25)01042-6. Epub 2025 Jul 28. Lancet. 2025. PMID: 40744051 Review. No abstract available.
CLCC1 governs ER bilayer equilibration to maintain lipid homeostasis.
Wu L, Wang J, Wang Y, Yang J, Yao Y, Wang Y, Huang D, Hu Y, Xu X, Wang R, Du W, Shi Y, Li Q, Liu L, Zhu Y, Li S, Chen FJ, Zhang X, Wang X, Guo Q, Xu L, Li P, Chen XW. Wu L, et al. Among authors: xu l. Nature. 2026 Apr;652(8109):471-480. doi: 10.1038/s41586-026-10161-y. Epub 2026 Feb 25. Nature. 2026. PMID: 41741642 Free PMC article.
To the Editor.
Zhen J, Zhao Z, Xu L. Zhen J, et al. Among authors: xu l. Menopause. 2025 Nov 1;32(11):1077. doi: 10.1097/GME.0000000000002663. Menopause. 2025. PMID: 41144254 No abstract available.
Epidemiology, clinical features, and molecular basis of TTMV::RARA-driven acute promyelocytic leukemia.
Zhou X, Chen J, Tang YL, Sun H, Chen Q, Chen X, Zhang Y, Fang J, Cao P, Ma X, Chen L, Xie Y, Wen L, Huang LB, Fan Z, Lou J, Xu W, Zhang N, Li J, Luo Y, Dai Y, Du H, Yang K, He Z, Yang X, Wang L, Liu B, Lin D, Zhang Y, Xu F, Zhang M, Wang Y, Yan S, Nan H, Zhang J, Xu L, Ma X, Tang R, Wang F, Yuan L, Liu M, Wang L, Wu Q, Zhang L, Liu S, Yan C, Zhou J, Lyu F, Wu P, Wang T, Zhang X, Lu Y, Liu D, Yang J, Xiong M, Zhao Y, Fan G, Xiao X, Ma F, Yang L, Luo XQ, Li J, Shen S, Zheng H, Chen S, Chen H, Zhao J, Zhang Z, Wang K, Lu P, Liu H. Zhou X, et al. Among authors: xu l. Blood. 2025 Oct 30;146(18):2229-2243. doi: 10.1182/blood.2025028674. Blood. 2025. PMID: 40811852
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study.
Qin S, Gu S, Chan SL, Bai Y, Ren Z, Lin X, Chen Z, Jia W, Jin Y, Guo Y, Hu X, Meng Z, Liang J, Xiong J, Ren H, Yang F, Li W, Chen Y, Zeng Y, Xu L, Yuan X, Li D, Sultanbaev A, Pazgan-Simon M, Pisetska M, Melisi D, Ponomarenko D, Du J, Shi W, Cheng AL, Kaseb A, Vogel A; CARES-310 Study Group. Qin S, et al. Among authors: xu l. Lancet Oncol. 2025 Dec;26(12):1598-1611. doi: 10.1016/S1470-2045(25)00543-1. Lancet Oncol. 2025. PMID: 41308676 Clinical Trial.
7,826 results